EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I
- Author
- DASSONVILLE, Olivier1 ; BOZEC, Alexandre1 ; FISCHEL, Jean Louis1 ; MILANO, Gerard1
[1] Centre Antoine Lacassagne, Laboratoire d'Oncopharmacologie, 33 Avenue de Vallombrose, 06189 Nice, France - Source
Critical reviews in oncology/hematology. 2007, Vol 62, Num 1, pp 53-61, 9 p ; ref : 105 ref
- ISSN
- 1040-8428
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Elsevier Science, Shannon
- Publication country
- Ireland
- Document type
- Article
- Language
- English
- Author keyword
- EGFR Monoclonal antibodies Targeted therapy Tyrosine kinase inhibitors
- Keyword (fr)
- Anticorps monoclonal Cancérologie Ciblage Etude comparative Immunothérapie Récepteur facteur croissance épiderme Traitement Inhibiteur de la tyrosine kinase Thérapeutique ciblée
- Keyword (en)
- Monoclonal antibody Cancerology Targeting Comparative study Immunotherapy Epidermal growth factor receptor Treatment Tyrosine kinase inhibitor Targeted therapy
- Keyword (es)
- Anticuerpo monoclonal Cancerología Blancado Estudio comparativo Inmunoterapia Receptor factor crecimiento epidermi Tratamiento Inhibidor tyrosine kinase Terapéutica blanca
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases
- Discipline
- Blood diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18611642
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:9:\"\u0000*\u0000jtitle\";s:39:\"Critical reviews in oncology\/hematology\";s:9:\"\u0000*\u0000stitle\";s:25:\"Crit. rev. oncol.\/hematol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"62\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"53\";s:8:\"\u0000*\u0000epage\";s:2:\"61\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1040-8428\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DASSONVILLE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Olivier\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"BOZEC, Alexandre\";i:1;s:19:\"FISCHEL, Jean Louis\";i:2;s:14:\"MILANO, Gerard\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:9:\"\u0000*\u0000jtitle\";s:39:\"Critical reviews in oncology\/hematology\";s:9:\"\u0000*\u0000stitle\";s:25:\"Crit. rev. oncol.\/hematol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"62\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"53\";s:8:\"\u0000*\u0000epage\";s:2:\"61\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1040-8428\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DASSONVILLE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Olivier\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"BOZEC, Alexandre\";i:1;s:19:\"FISCHEL, Jean Louis\";i:2;s:14:\"MILANO, Gerard\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:9:\"\u0000*\u0000jtitle\";s:39:\"Critical reviews in oncology\/hematology\";s:9:\"\u0000*\u0000stitle\";s:25:\"Crit. rev. oncol.\/hematol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"62\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"53\";s:8:\"\u0000*\u0000epage\";s:2:\"61\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1040-8428\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DASSONVILLE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Olivier\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"BOZEC, Alexandre\";i:1;s:19:\"FISCHEL, Jean Louis\";i:2;s:14:\"MILANO, Gerard\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:9:\"\u0000*\u0000jtitle\";s:39:\"Critical reviews in oncology\/hematology\";s:9:\"\u0000*\u0000stitle\";s:25:\"Crit. rev. oncol.\/hematol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"62\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"53\";s:8:\"\u0000*\u0000epage\";s:2:\"61\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1040-8428\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DASSONVILLE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Olivier\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"BOZEC, Alexandre\";i:1;s:19:\"FISCHEL, Jean Louis\";i:2;s:14:\"MILANO, Gerard\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:9:\"\u0000*\u0000jtitle\";s:39:\"Critical reviews in oncology\/hematology\";s:9:\"\u0000*\u0000stitle\";s:25:\"Crit. rev. oncol.\/hematol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"62\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"53\";s:8:\"\u0000*\u0000epage\";s:2:\"61\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1040-8428\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DASSONVILLE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Olivier\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"BOZEC, Alexandre\";i:1;s:19:\"FISCHEL, Jean Louis\";i:2;s:14:\"MILANO, Gerard\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:153:\"EGFR targeting therapies : Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences : Antibodies in cancer treatment - Part I\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
